Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 255

1.

Relation between clopidogrel active metabolite levels and different platelet aggregation methods in patients receiving clopidogrel and aspirin.

Liang Y, Johnston M, Hirsh J, Pare G, Li C, Mehta S, Teo KK, Sloane D, Yi Q, Zhu J, Eikelboom JW.

J Thromb Thrombolysis. 2012 Nov;34(4):429-36. doi: 10.1007/s11239-012-0762-2. Erratum in: J Thromb Thrombolysis. 2013 Jan;35(1):130.

PMID:
22797934
2.

A comparison of the antiplatelet effects of prasugrel and high-dose clopidogrel as assessed by VASP-phosphorylation and light transmission aggregometry.

Jakubowski JA, Payne CD, Li YG, Farid NA, Brandt JT, Small DS, Salazar DE, Winters KJ.

Thromb Haemost. 2008 Jan;99(1):215-22. doi: 10.1160/TH07-09-0555.

PMID:
18217157
3.

Which platelet function test is suitable to monitor clopidogrel responsiveness? A pharmacokinetic analysis on the active metabolite of clopidogrel.

Bouman HJ, Parlak E, van Werkum JW, Breet NJ, ten Cate H, Hackeng CM, ten Berg JM, Taubert D.

J Thromb Haemost. 2010 Mar;8(3):482-8. doi: 10.1111/j.1538-7836.2009.03733.x.

4.

Relation between the vasodilator-stimulated phosphoprotein phosphorylation assay and light transmittance aggregometry in East Asian patients after high-dose clopidogrel loading.

Kim IS, Jeong YH, Tantry US, Park Y, Lee DH, Bliden KP, Koh JS, Park JR, Jang JS, Hwang SJ, Koh EH, Kwak CH, Hwang JY, Kim S, Gurbel PA.

Am Heart J. 2013 Jul;166(1):95-103. doi: 10.1016/j.ahj.2013.03.030.

PMID:
23816027
5.

Comparison of conventional aggregometry with VASP for monitoring P2Y12-specific platelet inhibition.

Aradi D, Magyarlaki T, Tokés-Füzesi M, Rideg O, Vorobcsuk A, Komócsi A.

Platelets. 2010;21(7):563-70. doi: 10.3109/09537104.2010.494742.

PMID:
20642320
6.

[Platelet responsiveness to clopidogrel in patients with coronary syndrome. Comparison of platelet aggregation induced by ADP and flow cytometric analysis of intraplatelet VASP phosphorylation].

Morel O, Viellard C, Faure A, Jesel L, Ohlmann P, Desprez D, Chauvin M, Roul G, Grunebaum L, Bareiss P.

Ann Cardiol Angeiol (Paris). 2007 Jan;56(1):21-9. French.

PMID:
17343035
7.

Doubling the clopidogrel dose in patients with reduced responsiveness to the standard dose is associated with a limited effectiveness as evaluated by impedance aggregometry.

Stellbaum C, Ayral Y, Morguet A, Schultheiss HP, Rauch U.

Cardiovasc Revasc Med. 2012 May-Jun;13(3):159-66. doi: 10.1016/j.carrev.2012.02.009.

PMID:
22503564
8.

Higher body weight patients on clopidogrel maintenance therapy have lower active metabolite concentrations, lower levels of platelet inhibition, and higher rates of poor responders than low body weight patients.

Wagner H, Angiolillo DJ, Ten Berg JM, Bergmeijer TO, Jakubowski JA, Small DS, Moser BA, Zhou C, Brown P, James S, Winters KJ, Erlinge D.

J Thromb Thrombolysis. 2014;38(2):127-36. doi: 10.1007/s11239-013-0987-8.

PMID:
24043374
9.

Response to antiplatelet therapy is independent of endogenous thrombin generation potential.

Gremmel T, Panzer S, Steiner S, Seidinger D, Koppensteiner R, Pabinger I, Kopp CW, Ay C.

Thromb Res. 2013 Jul;132(1):e24-30. doi: 10.1016/j.thromres.2013.04.008.

PMID:
23623170
10.

Relationship between pharmacokinetics and pharmacodynamics of clopidogrel in patients undergoing percutaneous coronary intervention: comparison between vasodilator-stimulated phosphoprotein phosphorylation assay and multiple electrode aggregometry.

Danese E, Fava C, Beltrame F, Tavella D, Calabria S, Benati M, Gelati M, Gottardo R, Tagliaro F, Guidi GC, Cattaneo M, Minuz P.

J Thromb Haemost. 2016 Feb;14(2):282-93. doi: 10.1111/jth.13197.

PMID:
26576037
11.

Is TRAP-6 suitable as a positive control for platelet reactivity when assessing response to clopidogrel?

Gremmel T, Calatzis A, Steiner S, Kaider A, Seidinger D, Koppensteiner R, Kopp CW, Panzer S.

Platelets. 2010;21(7):515-21. doi: 10.3109/09537104.2010.493587.

PMID:
20624009
12.

Assessment of ADP-induced platelet aggregation with light transmission aggregometry and multiple electrode platelet aggregometry before and after clopidogrel treatment.

Sibbing D, Braun S, Jawansky S, Vogt W, Mehilli J, Schömig A, Kastrati A, von Beckerath N.

Thromb Haemost. 2008 Jan;99(1):121-6. doi: 10.1160/TH07-07-0478.

PMID:
18217143
13.

Sequential ADP-stimulated light transmission and multiple electrode aggregometry in patients taking aspirin and clopidogrel after non ST-elevation myocardial infarction.

Meen O, Brosstad F, Liestøl K, Kunszt G, Bendz B, Wettergreen M, Schjelderup NM, Andreassen T, Erikssen G.

Scand J Clin Lab Invest. 2012 Jul;72(4):318-25. doi: 10.3109/00365513.2012.666565.

PMID:
22724626
14.

The influencing factors for clopidogrel-mediated platelet inhibition are assay-dependent.

Gremmel T, Steiner S, Seidinger D, Koppensteiner R, Panzer S, Kopp CW.

Thromb Res. 2011 Oct;128(4):352-7. doi: 10.1016/j.thromres.2011.05.008.

PMID:
21621250
15.

The additive antiplatelet action of clopidogrel in patients with coronary artery disease treated with aspirin.

Dropinski J, Jakiela B, Sanak M, Wegrzyn W, Biernat M, Dziedzina S, Plutecka H, Szczeklik A.

Thromb Haemost. 2007 Jul;98(1):201-9.

PMID:
17598014
16.

Evaluation of the platelet count drop method for assessment of platelet function in comparison with "gold standard" light transmission aggregometry.

Lordkipanidzé M, Pharand C, Schampaert E, Palisaitis DA, Diodati JG.

Thromb Res. 2009 Sep;124(4):418-22. doi: 10.1016/j.thromres.2009.02.002.

PMID:
19250657
17.

Differential sensitivity and kinetics of response of different ex vivo tests monitoring functional variability of platelet response to clopidogrel.

Bal Dit Sollier C, Berge N, Boval B, Dubar M, Drouet L.

Thromb Haemost. 2010 Sep;104(3):571-81. doi: 10.1160/TH09-11-0803.

PMID:
20664906
18.

Multiple electrode aggregometry and vasodilator stimulated phosphoprotein-phosphorylation assay in clinical routine for prediction of postprocedural major adverse cardiovascular events.

Freynhofer MK, Brozovic I, Bruno V, Farhan S, Vogel B, Jakl G, Willheim M, Hübl W, Wojta J, Huber K.

Thromb Haemost. 2011 Aug;106(2):230-9. doi: 10.1160/TH11-02-0077.

PMID:
21614416
19.

The influence of body size on the pharmacodynamic and pharmacokinetic response to clopidogrel and prasugrel: a retrospective analysis of the FEATHER study.

Jakubowski JA, Angiolillo DJ, Zhou C, Small DS, Moser BA, Ten Berg JM, Brown PB, James S, Winters KJ, Erlinge D.

Thromb Res. 2014 Sep;134(3):552-7. doi: 10.1016/j.thromres.2014.05.019.

PMID:
25022828
20.

Pharmacodynamic effects of EV-077 in patients with diabetes mellitus and coronary artery disease on aspirin or clopidogrel monotherapy: results of an in vitro pilot investigation.

Rollini F, Tello-Montoliu A, Patel R, Darlington A, Wilson RE, Franchi F, Muñiz-Lozano A, Desai B, Bender N, Sakariassen KS, Angiolillo DJ.

J Thromb Thrombolysis. 2014;37(2):131-8. doi: 10.1007/s11239-013-0979-8.

PMID:
23943337

Supplemental Content

Support Center